おすすめの製品
製品名
Ro-20-1724, A cell-permeable, selective inhibitor of cAMP-specific phosphodiesterase (PDE IV; IC₅₀ = 2 µM).
品質水準
アッセイ
≥98% (TLC)
フォーム
solid
メーカー／製品名
Calbiochem®
保管条件
OK to freeze
色
white
溶解性
DMSO: 20%
ethanol: 4%
輸送温度
ambient
保管温度
10-30°C
SMILES記法
N1C(CNC1=O)Cc2cc(c(cc2)OC)OCCCC
InChI
1S/C15H22N2O3/c1-3-4-7-20-14-9-11(5-6-13(14)19-2)8-12-10-16-15(18)17-12/h5-6,9,12H,3-4,7-8,10H2,1-2H3,(H2,16,17,18)
InChI Key
PDMUULPVBYQBBK-UHFFFAOYSA-N
詳細
A cell-permeable, selective inhibitor of cAMP-specific phosphodiesterase (PDE IV; IC50 = 2 µM). Inhibits superoxide generation and arachidonic-induced platelet aggregation. Also inhibits fMLP-induced neutrophil adhesion to vascular endothelial cells.
Selective inhibitor of cAMP-specific phosphodiesterase (PDE IV, IC50 = 2 µM). Inhibits superoxide generation and arachidonic-induced platelet aggregation. Also inhibits fMLP-induced neutrophil adhesion to vascular endothelial cells.
生物化学的／生理学的作用
Cell permeable: yes
Primary Target
PDE IV
PDE IV
Product does not compete with ATP.
Reversible: no
Target IC50: 2 µM against PDE IV
警告
Toxicity: Irritant (B)
その他情報
Derian, C.K., et al. 1995. J. Immunol. 154, 308.
Rubin, L.L., et al. 1991. J. Cell Biol.115, 1725.
Lad, P.M., et al. 1985. Biochim. Biophys. Acta 846, 286.
Bergstrand, H., et al. 1977. Mol. Pharmacol.13, 38.
Rubin, L.L., et al. 1991. J. Cell Biol.115, 1725.
Lad, P.M., et al. 1985. Biochim. Biophys. Acta 846, 286.
Bergstrand, H., et al. 1977. Mol. Pharmacol.13, 38.
法的情報
CALBIOCHEM is a registered trademark of Merck KGaA, Darmstadt, Germany
保管分類コード
11 - Combustible Solids
WGK
WGK 3
引火点(°F)
Not applicable
引火点(℃)
Not applicable
適用法令
試験研究用途を考慮した関連法令を主に挙げております。化学物質以外については、一部の情報のみ提供しています。 製品を安全かつ合法的に使用することは、使用者の義務です。最新情報により修正される場合があります。WEBの反映には時間を要することがあるため、適宜SDSをご参照ください。
Jan Code
557502-MG:
557502-100MG:
試験成績書（COA）
製品のロット番号・バッチ番号を入力して、試験成績書（COA） を検索できます。ロット番号・バッチ番号は、製品ラベルに「Lot」または「Batch」に続いて記載されています。
Mohammad Keyvanloo Shahrestanaki et al.
Research in pharmaceutical sciences, 14(2), 107-114 (2019-10-18)
Diabetes incidence showed ascending trends in recent years indicating urgent need for new therapeutic agents. Extracellular adenosine signaling showed promising results. However, role of its A3 receptor in pancreatic β-cells proliferation and insulin secretion is not well established. Thus, we
Pieter J Gaillard et al.
Methods in molecular biology (Clifton, N.J.), 437, 161-175 (2008-03-29)
Drug delivery across the blood-brain barrier (BBB) is a major obstacle for the development of effective treatments of many central nervous system disorders. Sophisticated cell culture models of the BBB have helped us to identify, characterize, and validate a novel
Jeff A Beeler et al.
Methods in molecular biology (Clifton, N.J.), 237, 39-53 (2003-09-23)
This chapter outlines methods to purify soluble adenylyl cyclase (AC7) expressed in an Escherichia coli (E. coli) heterologous expression system. Guidelines are provided for constructing the expression plasmids, optimizing expression, culturing, and purifying the proteins. Purification requires two chromatographic steps.
Alejandro Sánchez-Melgar et al.
Frontiers in neuroscience, 15, 702817-702817 (2021-09-21)
Gliomas are the most common and aggressive primary tumors in the central nervous system. The nucleoside adenosine is considered to be one major constituent within the tumor microenvironment. The adenosine level mainly depends on two enzymatic activities: 5'-nucleotidase (5'NT or
Moumita Sarkar et al.
iScience, 25(7), 104527-104527 (2022-06-28)
The post-menopausal state in women is associated with increased cancer incidence, the reasons for which remain obscure. Curiously, increased circulating levels of beta-hCG (human chorionic gonadotropin) (a hormonal subunit linked with tumors of several lineages) are also often observed post-menopause.
アクティブなフィルタ
ライフサイエンス、有機合成、材料科学、クロマトグラフィー、分析など、あらゆる分野の研究に経験のあるメンバーがおります。.
製品に関するお問い合わせはこちら（テクニカルサービス）
